Skip To Main Content
Ming-Lung Yu on Muck Rack

Ming-Lung Yu

As seen in: Nature, Wiley Online Library, BMJ Open, Gut Journal, Taylor & Francis Online, The Lancet, Dove Medical Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ming-Lung

Contact Ming-Lung, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Editorial: Liver and Non-Liver Outcomes Between Different Subtypes of Steatotic Liver Disease

|
By Jee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang
| Wiley Online Library Verified
Steatotic liver disease (SLD) is the most prevalent liver non-communicable disease affecting more than one-third of the global population. With the new nomenclature proposed in recent years by the major societies, the elucidation of the disease course and outcomes of SLD is a mandatory task clinically [1, 2]. The specific question is: How're the differences of liver and cardiovascular outcomes between the major subtypes of SLD?
Open in Who Shared Issue with article?

Hepatitis C elimination: is it time to redefine the goals? - Nature Reviews Gastroenterology & Hepatology

|
By Yasser Mahrous Fouad, Ming-Lung Yu, Saeed Hamid, Robert G. Gish, Mohammed Eslam
| Nature Verified
Direct-acting antiviral agents have substantially improved the rate of sustained virologic response and safety in the treatment of hepatitis C. However, concerns about the long-term outcomes for individuals who achieve sustained virologic response still exist. Herein, we propose a new conceptual model for redefining the goals and strategies of ongoing hepatitis C elimination campaigns.
Open in Who Shared Issue with article?

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' Reply

|
By Pei-Chien Tsai, Jee-Fu Huang, Ming-Lung Yu
| Wiley Online Library Verified
We appreciate the insightful commentary by Wakabayashi et al. regarding the shifting paradigm in hepatitis C virus (HCV) care from a singular focus on viral clearance to the long-term management of residual intrahepatic and extrahepatic risks. Their editorial accurately underscores that the intersection of steatotic liver disease (SLD) and major adverse cardiovascular events (MACEs) has emerged as a critical frontier in post-SVR clinical care [1].
Open in Who Shared Issue with article?
See all 12 articles